Videos

Crystal Lennartz, PharmD, MBA, discusses independent pharmacy resilience, recent industry recognitions, and new tools announced at McKesson ideaShare 2026 to support pharmacy growth and transparency.

This OPC interview discusses emerging standards of care in genitourinary cancers, the growing role of molecular testing and minimal residual disease monitoring, and how oncology pharmacists can optimize treatment management.

This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.

Chris Van Norman discusses how technology, automation, and dedicated frontline teams keep the company's supply chain resilient and patient-focused.

Nancy Lyons, vice president and chief pharmacy officer at Health Mart, explains how McKesson Amplify and pharmacist-told patient care stories are driving advocacy wins for independent pharmacies at the state and federal levels.

This interview discusses candidate selection, toxicity monitoring, access considerations, and evolving clinical applications of menin inhibitors in acute myeloid leukemia (AML).

How oncology pharmacists evaluate emerging clinical data, overcome implementation barriers, and stay current with rapidly evolving advances in precision oncology.

Phase 3 SKYLIGHT and OASIS trials show rapid, week-one relief of menopausal hot flashes, with key safety findings and mixed sleep benefits.

New NK3 receptor blockers target hypothalamic “KNDy” neurons, easing menopause hot flashes without hormones and gaining top guideline support.

Niki Shah, MHSA, MBA, CCHW, discusses how Project Oasis, a new diabetic retinopathy screening pilot, and the company's Community Health Worker scholarship program are working together to reduce barriers to care in under-resourced communities

The growing role of biomarker-driven treatment selection in breast cancer and how pharmacists can help optimize therapy sequencing, toxicity management, and personalized care.

Key distinctions among bispecific therapies, toxicity management considerations, and the pharmacist’s role in safely implementing these agents across academic and community oncology settings.

Cheeley maps out the resources—courses, certifications, communities, and a retail pharmacy call to action—that can take any pharmacist deeper into lipid management.

Chiadi Ndumele, MD, explains why the new American Heart Association (AHA)/American College of Cardiology (ACC) guideline addresses cardiovascular-kidney-metabolic (CKM) disease as one interconnected syndrome.

Fátima Rodriguez, MD, explains how the new cardiovascular-kidney-metabolic (CKM) syndrome guideline addresses health equity, risk prediction, and the pharmacist's role in care.

Cheeley takes listeners inside her clinical decision-making process—from statin intolerance to PCSK9 inhibitors to omega-3s—and explains why patient buy-in is as important as the prescription itself.

Leaders unpack governance, SOP scalability, and payer hurdles in cell and gene therapy program development, helping the cell and gene therapies community build sustainable programs.

Jaimee Colvin, MSN, APRN, FNP-C, outlines the intentional, community-rooted, and representation-driven infrastructure required to scale PrEP access for cisgender women nationally.

Correcting the misinformation around statins and cardiovascular disease, and reframing Lp(a) as a genetic condition, not a personal failure, can be a powerful clinical tool.

Craig Beavers, PharmD, discusses transthyretin amyloidosis cardiomyopathy (ATTR-CM) red flags, treatment evidence, and how pharmacists can drive earlier diagnosis and improve patient outcomes.

From prior authorization barriers to population health gaps, Cheeley explains why adherence — not initiation — is where pharmacists can make their biggest impact.

This week's episode covers the first-ever joint guidelines for cardiovascular-kidney-metabolic syndrome, key highlights from ASCO 2026 and ADA 2026, and new FDA approvals in diabetes, infectious diseases, and pain management.

Persistent HIV stigma, provider reluctance, and harmful misconceptions about who PrEP is for continue to prevent cisgender Black and Brown women from accessing lifesaving prevention.

Pharmacy Times speaks with Matt Christian, the Director of Supply Chain Insights at US Pharmacopeia (USP), about the factors driving persistent drug shortages, emerging supply chain vulnerabilities, and what pharmacists should know moving forward.

New NK3 receptor blockers target hypothalamic ‘KNDy’ neurons, offering

How pharmacists can spot menopause beyond hot flashes, update hormone therapy knowledge, and collaborate on dosing amid estrogen patch shortages.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Jessica Dunne, PhD, discusses why adult type 1 diabetes (T1D) is frequently misdiagnosed as T2D in patients with gestational diabetes mellitus (GDM) and how autoantibody testing could close the diagnostic gap.

Pharmacy Times interviews Tracey Taveira, Pharm.D., CDOE, CVDOE, on the key challenges she discovered in optimizing cardio-renal risk in diabetes that she presented in ADA 2026.

Stephanie Dwyer Kaluzna, PharmD, BCCP, discusses atrial fibrillation (AFib) anticoagulation risk stratification, therapy selection, and the emerging role of factor XI/XIa inhibitors.